1. JAK-2 V617F Mutational Analysis in Primary Idiopathic Myelofibrosis: Experience from Southern Pakistan
   Sadia Sultan et al, 2015, Asian Pacific Journal of Cancer Prevention CrossRef
2. Detection of JAK2 Exon 12 Mutations in JAK2 V617F-Negative Polycythemia Vera Patients by Cloning Technique
   Aleksandra Leszczynska et al, 2016, Acta Haematologica CrossRef
3. Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia
   Hironori Arai et al, 2022, Biomedicines CrossRef
4. Relationship betweenJAK2V617Fmutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms
   Linhui Hu et al, 2017, Hematology CrossRef
5. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
   Srdan Verstovsek et al, 2017, Blood CrossRef
6. Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular
   Renato Sampaio Tavares et al, 2019, Hematology, Transfusion and Cell Therapy CrossRef
7. Clinical and Laboratory Features of JAK2 V617F, CALR, and MPL Mutations in Malaysian Patients with Classical Myeloproliferative Neoplasm (MPN)
   Razan Hayati Zulkeflee et al, 2021, International Journal of Environmental Research and Public Health CrossRef
8. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms
   Sérgio Ferreira Cristina et al, 2018, Seminars in Hematology CrossRef
9. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973–2011
   Melissa A. Deadmond et al, 2015, Journal of Cancer Research and Clinical Oncology CrossRef